FDA approves new treatment for serious lung cancer

05/6/2003 | Philadelphia Inquirer, The · NYTimes.com

Lung cancer patients who have not responded well to chemotherapy will now have the option of taking Iressa, a new drug from AstraZeneca that disrupts the chemical makeup of tumors. The FDA's approval of the drug, despite a significant threat of serious side effects, may signal a change in the way the FDA handles approval for life-threatening illnesses.

View Full Article in:

Philadelphia Inquirer, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY